thiorphan has been researched along with Body Weight in 8 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction." | 7.70 | Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. ( Anastasopoulos, F; Briscoe, TA; Campbell, DJ; Duncan, AM; James, GM; Kladis, A, 1999) |
| " Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction." | 3.70 | Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. ( Anastasopoulos, F; Briscoe, TA; Campbell, DJ; Duncan, AM; James, GM; Kladis, A, 1999) |
| " Thus, optimal neprilysin inhibitor dosing reveals additional cardioprotective effects on top of AT1 receptor blockade in renin-dependent hypertension." | 1.42 | Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. ( Batenburg, WW; Bhaggoe, UM; Clahsen-van Groningen, MC; de Vries, R; Domenig, O; Friesema, EC; Garrelds, IM; Hoorn, EJ; Jan Danser, AH; Leijten, FP; Poglitsch, M; Roksnoer, LC; van Veghel, R, 2015) |
| " The dose-response curve for ET-1 was shifted to the left in the diabetics, so that at some lower doses of ET-1 the vasoconstriction was greater than in the controls." | 1.36 | Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. ( Kamata, K; Kobayashi, T; Matsumoto, T; Ozawa, Y; Taguchi, K, 2010) |
| " Similarly, chronic dosing with acetorphan after withdrawal produced no significant effect on body weight." | 1.27 | Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. ( Livingston, SJ; Rooney, KF; Sewell, RD; Smith, HJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roksnoer, LC | 1 |
| van Veghel, R | 1 |
| de Vries, R | 1 |
| Garrelds, IM | 1 |
| Bhaggoe, UM | 1 |
| Friesema, EC | 1 |
| Leijten, FP | 1 |
| Poglitsch, M | 1 |
| Domenig, O | 1 |
| Clahsen-van Groningen, MC | 1 |
| Hoorn, EJ | 1 |
| Jan Danser, AH | 1 |
| Batenburg, WW | 1 |
| Matsumoto, T | 1 |
| Ozawa, Y | 1 |
| Taguchi, K | 1 |
| Kobayashi, T | 1 |
| Kamata, K | 1 |
| Stasch, JP | 1 |
| Knorr, A | 1 |
| Wegner, M | 1 |
| Hirth-Dietrich, C | 1 |
| Duncan, AM | 1 |
| James, GM | 1 |
| Anastasopoulos, F | 1 |
| Kladis, A | 1 |
| Briscoe, TA | 1 |
| Campbell, DJ | 1 |
| Maldonado, R | 2 |
| Fournié-Zaluski, MC | 2 |
| Roques, BP | 2 |
| Schulz, R | 1 |
| Sakane, Y | 1 |
| Berry, C | 1 |
| Ghai, R | 1 |
| Daugé, V | 1 |
| Callebert, J | 1 |
| Villette, JM | 1 |
| Feger, J | 1 |
| Livingston, SJ | 1 |
| Sewell, RD | 1 |
| Rooney, KF | 1 |
| Smith, HJ | 1 |
8 other studies available for thiorphan and Body Weight
| Article | Year |
|---|---|
Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Atrial Natriuretic Factor; Biph | 2015 |
Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction.
Topics: Animals; Aspartic Acid Endopeptidases; Benzofurans; Blood Glucose; Body Weight; Coronary Vessels; Di | 2010 |
Prolonged inhibition of neutral endopeptidase 24.11 by sinorphan in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Heart Failure; Hemodynamics; Kidney | 1995 |
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Bradykinin; Cardiome | 1999 |
Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.
Topics: Analgesics; Animals; Behavior, Animal; Body Temperature; Body Weight; Corticosterone; Dipeptides; En | 1992 |
Characterisation of neutral endopeptidase 3.4.24.11 (NEP) in the kidney: comparison between normotensive, genetically hypertensive and experimentally hypertensive rats.
Topics: Animals; Body Weight; Desoxycorticosterone; DNA; Glycopeptides; Hot Temperature; Hydrogen-Ion Concen | 1991 |
Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Corticosterone; Dipeptides; Hydroxamic Aci | 1989 |
Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.
Topics: Amino Acids, Sulfur; Analgesics; Animals; Body Temperature; Body Weight; Male; Metalloendopeptidases | 1988 |